Puma Biotechnology | PBYI - Equity Capital And Reserves


Puma Biotechnology reported $115.27M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
Exelixis USD 2.16B 619K Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Glaxosmithkline GBP 21.7B 7.35B Sep/2025
Incyte USD 5.17B 516.28M Dec/2025
MacroGenics USD 67M 20.38M Sep/2025
Moderna USD 8.65B 680M Dec/2025
Novartis USD 44.75B 2.7B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Takeda JPY 7.64T 513.39B Dec/2025
TG Therapeutics USD 648.02M 40.8M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025